NKR-P1F, a receptor within the Natural Killer (NK) cell receptor family, plays an integral role in the innate immune system, specifically in the regulation of NK cell activity against virally infected and malignant cells. Its primary function hinges on its ability to recognize specific ligands expressed by target cells, thereby activating NK cells to exert cytotoxic effects and secrete cytokines crucial for the immune response. This receptor-mediated activation is essential for the rapid and targeted response to infected or transformed cells, facilitating the clearance of these cells while minimizing collateral damage to healthy tissues. The specificity and efficacy of NKR-P1F in immune surveillance underscore its importance in maintaining the delicate balance between immune responsiveness and tolerance.
The inhibition of NKR-P1F is a complex process that involves multiple regulatory mechanisms aimed at preventing excessive or inappropriate activation of NK cells, which could lead to autoimmune reactions or tissue damage. One primary mechanism of NKR-P1F inhibition involves the engagement with specific ligands that either block the receptor's ability to bind to its activating ligands or deliver inhibitory signals that counteract the activation signals. These inhibitory ligands can be expressed by normal cells as a means of self-protection or by tumor cells as a mechanism of immune evasion. Additionally, the regulatory framework for NKR-P1F activity includes the expression of soluble factors and the interaction with other inhibitory receptors on NK cells, which can modulate the threshold for activation and ensure the precision of NK cell responses. The integration of these inhibitory signals is crucial for maintaining the balance of NK cell activity, preventing overactivation, and preserving the integrity of healthy tissues. Understanding the intricacies of NKR-P1F inhibition provides valuable insights into the regulatory mechanisms that underpin the immune response, highlighting the sophistication of immune regulation at the cellular and molecular levels.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinases (PI3K). NKR-P1F is known to function in PI3K signaling pathways, and by inhibiting PI3K, LY294002 can lead to a decrease in the activity of NKR-P1F as a downstream effector. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent PI3K inhibitor. Its inhibition of PI3K disrupts the signaling pathway that NKR-P1F is involved in, leading to decreased functional activity of NKR-P1F. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
BKM120 is a specific and potent inhibitor of PI3K. By inhibiting PI3K, which is a key component of the signaling pathway NKR-P1F is involved in, BKM120 can lead to decreased functional activity of NKR-P1F. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), which is a downstream effector of the PI3K pathway. The inhibition of mTOR can disrupt the PI3K signaling pathway, thus indirectly leading to decreased functional activity of NKR-P1F. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent, selective, and bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor. Its inhibition of mTOR can disrupt the PI3K signaling pathway, thus indirectly leading to decreased functional activity of NKR-P1F. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor. Its inhibition of mTOR can disrupt the PI3K signaling pathway, thus indirectly leading to decreased functional activity of NKR-P1F. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a potent, cell-permeable, ATP-competitive and selective inhibitor of PI3K family members. By inhibiting PI3K, PI-103 can lead to decreased functional activity of NKR-P1F. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
BEZ235 is a dual PI3K/mTOR inhibitor. Its inhibition of both PI3K and mTOR can disrupt the PI3K signaling pathway, thus leading to decreased functional activity of NKR-P1F. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is a selective class I phosphatidylinositol 3-kinase inhibitor. Its inhibition of PI3K can lead to a decrease in the activity of NKR-P1F. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941's inhibition of PI3K can lead to a decrease in the activity of NKR-P1F. | ||||||